Daniel Benny
Esophageal carcinoma is a challenging malignancy with limited treatment options and poor prognosis, necessitating the exploration of novel therapeutic strategies. Metformin, a widely used drug for type 2 diabetes, has shown promising anticancer effects in various malignancies, including esophageal carcinoma. This article provides an overview of the molecular mechanisms underlying the anticancer properties of metformin in esophageal carcinoma and discusses its therapeutic potential.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 